Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HepeX-B
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HepeX-B is an investigational biologic therapy consisting of a mixture of two human monoclonal antibodies (mAbs) directed against the Hepatitis B surface antigen (HBsAg). Developed by Cubist Pharmaceuticals (a subsidiary of Merck & Co.) in collaboration with XTL Biopharmaceuticals, it was designed for the prevention of Hepatitis B virus (HBV) reinfection in patients undergoing liver transplantation for HBV-related end-stage liver disease. The drug was intended to serve as a more standardized and potent alternative to plasma-derived Hepatitis B Immune Globulin (HBIg) by neutralizing circulating HBV particles and preventing the infection of the new liver graft. Clinical development reached Phase 2b, but the program was ultimately discontinued following strategic shifts and the acquisition of Cubist by Merck.
- Other names
- HepeX-B
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on HepeX-B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HepeX-B.